Recommended dose of alfacacidol for osteoporosis.

Abstract

The present study aims to investigate a proper dose of alfacalcidol by using the parathyroid level as a marker due to the end product of alfacalcidol is calcitriol which has a property of suppression secretion of parathyroid glands. The research enrolled 259 volunteers which were divided into 2 groups. Each group took the elemental calcium 800 milligram plus alfacalcidol at the different doses. Group (A) received alfacalcidol 1.0 microgram/day and Group (B) had alfacalcidol 1.5 micrograms/day for 3 months. Group (A) could not suppress the secretion of PTH compared with Group (B) of which the PTH level was decreased significantly (p = 0.047). Alfacalcidol in both groups can not decrease the bone resorption monitored by using the bone resorption marker, BetacrossLaps or bCTx.

• Authors: Narong Bunyaratavej
• Journal: Journal of the Medical Association of Thailand = Chotmaihet thangphaet (J Med Assoc Thai) Vol. 94 Suppl 5 Pg. S7-9 (Oct 2011) ISSN: 0125-2208 [Print] Thailand
• PMID: 22338919 (Publication Type: Journal Article)

Chemical References

• Bone Density Conservation Agents
• Hydroxycholecalciferols
• alfacalcidol

Topics

• Bone Density Conservation Agents (administration & dosage)
• Female
• Humans
• Hydroxycholecalciferols (administration & dosage)
• Middle Aged
• Osteoporosis, Postmenopausal (drug therapy)